Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

Abstract Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CRVOs) previously treated with ranibizumab...

Full description

Bibliographic Details
Main Authors: Rahul N. Khurana, Louis K. Chang, Alok S. Bansal, James D. Palmer, Chengqing Wu, Mark R. Wieland
Format: Article
Language:English
Published: BMC 2019-04-01
Series:International Journal of Retina and Vitreous
Subjects:
Central retinal vein occlusion
Macular edema
Chronic
Treat and extend
Aflibercept
Ranibizumab
Online Access:http://link.springer.com/article/10.1186/s40942-019-0159-x

Internet

http://link.springer.com/article/10.1186/s40942-019-0159-x

Similar Items